{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:29:37Z","timestamp":1792787377357,"version":"4.5.0"},"reference-count":91,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma in which immunochemotherapy, with or without high-dose therapy, and autologous stem cell transplantation remain standard frontline therapies. Despite their clear efficacy, patients inevitably relapse and require subsequent therapy. In this review, we discuss the key therapeutic approaches in the management of relapsed MCL, covering in depth the data supporting the use of covalent Bruton tyrosine kinase (BTK) inhibitors at first or subsequent relapse. We describe the outcomes of patients progressing through BTK inhibitors and discuss the mechanisms of covalent BTKi resistance and treatment options after covalent treatment with BTKi. Options in this setting may depend on treatment availability, patient\u2019s and physician\u2019s preference, and the patient\u2019s age and comorbidity status. We discuss the rapid recent development of anti-CD19 chimeric antigen receptor T-cell therapy, as well as the utility of allogenic stem cell transplantation and novel therapies, such as noncovalent, reversible BTK inhibitors; ROR1 antibody drug conjugates; and bispecific antibodies.<\/jats:p>","DOI":"10.1182\/blood.2021013326","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T23:25:59Z","timestamp":1634945159000},"page":"666-677","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":78,"title":["Therapeutic options for relapsed\/refractory mantle cell lymphoma"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"first","affiliation":[{"name":"Haematology and Cancer Centre, Oxford University Hospitals National Health Service (NHS) Foundation Trust, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-1565","authenticated-orcid":false,"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[{"name":"Department of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australia;"},{"name":"Medical School, University of Western Australia, Perth, WA, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2022020316231843900_B1","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood."},{"issue":"13","key":"2022020316231843900_B2","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med."},{"issue":"6","key":"2022020316231843900_B3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med."},{"issue":"3","key":"2022020316231843900_B4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly Trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J Clin Oncol."},{"issue":"9873","key":"2022020316231843900_B5","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet."},{"issue":"10","key":"2022020316231843900_B6","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med."},{"issue":"11","key":"2022020316231843900_B7","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","article-title":"Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study","volume":"19","author":"Robak","year":"2018","journal-title":"Lancet Oncol."},{"key":"2022020316231843900_B8","doi-asserted-by":"crossref","DOI":"10.1002\/hon.61_2880","article-title":"Role of maintenance rituximab after first-line bendamustine + rituximab or R-CHOP in patients with mantle cell lymphoma from a large US real-world cohort [abstract]","volume":"39","author":"Wang","year":"2021","journal-title":"Hematol Oncol."},{"key":"2022020316231843900_B9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-138731","article-title":"Initial treatment with lenalidomide plus rituximab for mantle cell lymphoma (MCL): 7-year analysis from a multi-center phase 2 study [oral abstract]","volume":"136","author":"Y","year":"2020","journal-title":"Blood."},{"issue":"19","key":"2022020316231843900_B10","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med."},{"key":"2022020316231843900_B11","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-125800","article-title":"Frontline treatment with ibrutinib with rituximab (IR) combination is highly effective in elderly (\u226565 years) patients with mantle cell lymphoma (MCL) - results from a phase 2 trial [abstract]","volume":"134","author":"Jain","year":"2019","journal-title":"Blood."},{"key":"2022020316231843900_B12","doi-asserted-by":"crossref","DOI":"10.1002\/hon.61_2879","article-title":"The combination of venetoclax, lenalidomide and rituximab in patients with newly diagnosed mantle cell lymphoma induces high response rates and MRD undetectability [abstract]","volume":"39","author":"Phillips","year":"2021","journal-title":"Hematol Oncol."},{"issue":"7","key":"2022020316231843900_B13","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood."},{"issue":"3","key":"2022020316231843900_B14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","article-title":"Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study [published correction appears in Leukemia. 2021;35(3):932]","volume":"35","author":"Visco","year":"2021","journal-title":"Leukemia."},{"issue":"2","key":"2022020316231843900_B15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.17513","article-title":"Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: a UK and Ireland analysis","volume":"194","author":"Rampotas","year":"2021","journal-title":"Br J Haematol."},{"issue":"5","key":"2022020316231843900_B16","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/bjh.15643","article-title":"Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death","volume":"185","author":"Visco","year":"2019","journal-title":"Br J Haematol."},{"issue":"2","key":"2022020316231843900_B17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/bjh.17363","article-title":"Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients","volume":"193","author":"McCulloch","year":"2021","journal-title":"Br J Haematol."},{"issue":"12","key":"2022020316231843900_B18","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Halld\u00f3rsd\u00f3ttir","year":"2011","journal-title":"Leukemia."},{"issue":"5","key":"2022020316231843900_B19","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica."},{"issue":"17","key":"2022020316231843900_B20","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood."},{"issue":"3","key":"2022020316231843900_B21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol."},{"issue":"11","key":"2022020316231843900_B22","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/cncr.31328","article-title":"Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy","volume":"124","author":"Greenwell","year":"2018","journal-title":"Cancer."},{"issue":"1","key":"2022020316231843900_B23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.2012.44.4281","article-title":"Targeting B-Cell receptor signaling for anticancer therapy: the Bruton\u2019s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies","volume":"31","author":"Wiestner","year":"2013","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022020316231843900_B24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med."},{"issue":"10020","key":"2022020316231843900_B25","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet."},{"issue":"1","key":"2022020316231843900_B26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol."},{"issue":"10121","key":"2022020316231843900_B27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet."},{"key":"2022020316231843900_B28","doi-asserted-by":"crossref","first-page":"hon.58_2880","DOI":"10.1002\/hon.58_2880","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma: final results from a phase 2 study [abstract]","volume":"39","author":"Wang","year":"2021","journal-title":"Hematol Oncol."},{"issue":"11","key":"2022020316231843900_B29","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1038\/s41375-021-01252-y","article-title":"Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies","volume":"35","author":"Furman","year":"2021","journal-title":"Leukemia."},{"issue":"16","key":"2022020316231843900_B30","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton\u2019s tyrosine kinase","volume":"26","author":"So","year":"2020","journal-title":"Clin Cancer Res."},{"key":"2022020316231843900_B31","article-title":"Zanubrutinib (Zanu) in patients (Pts) with relapsed\/refractory (R\/R) mantle cell lymphoma (Mcl): long-term efficacy and safety results from a phase 2 study [abstract]","author":"Song","year":"2021","journal-title":"Eur Hematol Assoc."},{"issue":"12","key":"2022020316231843900_B32","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv."},{"key":"2022020316231843900_B33","doi-asserted-by":"crossref","DOI":"10.1002\/hon.33_2879","article-title":"First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia [abstract]","volume":"39","author":"Hillmen","year":"2021","journal-title":"Hematol Oncol."},{"issue":"18","key":"2022020316231843900_B34","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood."},{"key":"2022020316231843900_B35","article-title":"First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma [abstract]","author":"Hillmen","year":"2021","journal-title":"Eur Hematol Assoc."},{"issue":"3","key":"2022020316231843900_B36","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet Haematol."},{"key":"2022020316231843900_B37","doi-asserted-by":"crossref","first-page":"hon.62_2879","DOI":"10.1002\/hon.62_2879","article-title":"SAKK 36\/13 \u2013 ibrutinib plus bortezomib and ibrutinib maintenance for relapsed and refractory mantle cell lymphoma: final report of a Phase I\/II trial of the European MCL Network","volume":"39","author":"Novak","year":"2021","journal-title":"Hematol Oncol."},{"issue":"1","key":"2022020316231843900_B38","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol."},{"issue":"11","key":"2022020316231843900_B39","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","article-title":"A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma [published correction appears in Blood. 2019;134(11):908]","volume":"133","author":"Martin","year":"2019","journal-title":"Blood."},{"issue":"13","key":"2022020316231843900_B40","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med."},{"issue":"3","key":"2022020316231843900_B41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial","volume":"17","author":"Trn\u011bn\u00fd","year":"2016","journal-title":"Lancet Oncol."},{"issue":"3","key":"2022020316231843900_B42","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol."},{"key":"2022020316231843900_B43","first-page":"3822","article-title":"Phase 3 study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","author":"Hess","year":"2009"},{"issue":"8","key":"2022020316231843900_B44","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","article-title":"Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network","volume":"24","author":"Cheah","year":"2013","journal-title":"Ann Oncol."},{"issue":"9","key":"2022020316231843900_B45","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3109\/10428194.2013.767454","article-title":"Risk factors of central nervous system relapse in mantle cell lymphoma","volume":"54","author":"Conconi","year":"2013","journal-title":"Leuk Lymphoma."},{"issue":"5","key":"2022020316231843900_B46","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdv074","article-title":"Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL)","volume":"26","author":"Chihara","year":"2015","journal-title":"Ann Oncol."},{"issue":"4","key":"2022020316231843900_B47","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdz032","article-title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u2018proof of concept\u2019 phase 2 study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann Oncol."},{"issue":"5","key":"2022020316231843900_B48","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"Grommes","year":"2019","journal-title":"Blood."},{"key":"2022020316231843900_B49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase 2 \u2018proof-of-concept\u2019 iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer."},{"key":"2022020316231843900_B50","article-title":"Ibrutinib compared to immuno-chemotherapy for central nervous system relapse of mantle cell lymphoma: a report from Fondazione Italiana Linfomi (FIL) and European Mantle Cell Lymphoma Network (EMCLN) [abstract]","author":"Rusconi","year":"2020","journal-title":"Eur Hematol Assoc."},{"key":"2022020316231843900_B51","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005292","article-title":"CAR T-cell therapy for secondary CNS DLBCL [published online ahead of print 22 September 2021]","author":"Ahmed","year":"2021","journal-title":"Blood Adv."},{"issue":"20","key":"2022020316231843900_B52","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/bloodadvances.2020004106","article-title":"CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma","volume":"5","author":"Siddiqi","year":"2021","journal-title":"Blood Adv."},{"key":"2022020316231843900_B53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2020-136158","article-title":"Safety and preliminary efficacy in patients with relapsed\/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in transcend NHL 001","volume":"136","author":"Palomba","year":"2020","journal-title":"Blood."},{"issue":"12","key":"2022020316231843900_B54","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood."},{"issue":"6","key":"2022020316231843900_B55","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol."},{"issue":"4","key":"2022020316231843900_B56","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/hon.2380","article-title":"Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma-a \u201creal world\u201d study","volume":"35","author":"Epperla","year":"2017","journal-title":"Hematol Oncol."},{"issue":"6","key":"2022020316231843900_B57","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/bjh.16739","article-title":"The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed\/refractory mantle cell lymphoma","volume":"192","author":"Tucker","year":"2021","journal-title":"Br J Haematol."},{"issue":"11","key":"2022020316231843900_B58","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","article-title":"Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia."},{"issue":"24","key":"2022020316231843900_B59","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med."},{"issue":"1","key":"2022020316231843900_B60","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med."},{"issue":"25","key":"2022020316231843900_B61","doi-asserted-by":"crossref","first-page":"38180","DOI":"10.18632\/oncotarget.9500","article-title":"Genetic heterogeneity in primary and relapsed mantle cell lymphomas: impact of recurrent CARD11 mutations","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget."},{"issue":"45","key":"2022020316231843900_B62","doi-asserted-by":"crossref","first-page":"73558","DOI":"10.18632\/oncotarget.12434","article-title":"CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma","volume":"7","author":"Mohanty","year":"2016","journal-title":"Oncotarget."},{"issue":"4","key":"2022020316231843900_B63","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2017-04-776740","article-title":"SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma","volume":"130","author":"Balsas","year":"2017","journal-title":"Blood."},{"issue":"491","key":"2022020316231843900_B64","doi-asserted-by":"crossref","first-page":"eaau1167","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci Transl Med."},{"issue":"11","key":"2022020316231843900_B65","doi-asserted-by":"crossref","first-page":"108870","DOI":"10.1016\/j.celrep.2021.108870","article-title":"Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma","volume":"34","author":"Zhao","year":"2021","journal-title":"Cell Rep."},{"issue":"1","key":"2022020316231843900_B66","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1038\/s41467-021-22872-z","article-title":"Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun."},{"issue":"1","key":"2022020316231843900_B67","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13045-017-0537-5","article-title":"Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib (MCL-004)","volume":"10","author":"Wang","year":"2017","journal-title":"J Hematol Oncol."},{"issue":"2","key":"2022020316231843900_B68","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica."},{"issue":"6","key":"2022020316231843900_B69","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ajh.25796","article-title":"Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) \u2013 outcomes and mutation profile from venetoclax resistant MCL patients","volume":"95","author":"Zhao","year":"2020","journal-title":"Am J Hematol."},{"key":"2022020316231843900_B70","doi-asserted-by":"crossref","DOI":"10.1002\/hon.85_2881","article-title":"Preliminary safety data from patients (pts) with relapsed\/refractory (R\/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (bcl2) inhibitor BGB-11417 [abstract]","volume":"39","author":"Cheah","year":"2021","journal-title":"Hematol Oncol."},{"issue":"4","key":"2022020316231843900_B71","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16416","article-title":"Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy","volume":"189","author":"McCulloch","year":"2020","journal-title":"Br J Haematol."},{"issue":"1","key":"2022020316231843900_B72","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi","volume":"4","author":"Visco","year":"2017","journal-title":"Lancet Haematol."},{"key":"2022020316231843900_B73","first-page":"514","article-title":"Allogeneic stem cell transplantation can be successfully delivered following BTKI therapy failure following R-bac Re-induction chemotherapy in patients with mantle cell lymphoma","volume":"55","author":"Lewis","year":"2020","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"2022020316231843900_B74","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/cancers13020291","article-title":"Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy","volume":"13","author":"Marangon","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"1","key":"2022020316231843900_B75","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"issue":"14","key":"2022020316231843900_B76","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med."},{"key":"2022020316231843900_B77","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-139063","article-title":"One-year follow-up of ZUMA-2, the multicenter, registrational study of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma [poster abstract]","volume":"136","author":"Wang","year":"2020","journal-title":"Blood."},{"key":"2022020316231843900_B78","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1200\/JCO.2021.39.15_suppl.7547","article-title":"Outcomes with KTE-X19 in patients (pts) with relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24)","volume":"39","author":"Wang","year":"2021","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022020316231843900_B79","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","article-title":"Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties","volume":"54","author":"Dreger","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"2022020316231843900_B80","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41409-017-0067-3","article-title":"Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party","volume":"53","author":"Robinson","year":"2018","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"2022020316231843900_B81","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bjh.15721","article-title":"Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations","volume":"184","author":"Lin","year":"2019","journal-title":"Br J Haematol."},{"key":"2022020316231843900_B82","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-021-01288-9","article-title":"ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma","author":"Munshi","year":"2021","journal-title":"Bone Marrow Transplant."},{"issue":"13","key":"2022020316231843900_B83","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-Mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol."},{"key":"2022020316231843900_B84","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-137237","article-title":"LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma, Waldenstr\u00f6m\u2019s macroglobulinemia, and other non-Hodgkin lymphomas: results from the phase 1\/2 BRUIN study [oral abstract]","volume":"136","author":"Wang","year":"2020","journal-title":"Blood."},{"issue":"10277","key":"2022020316231843900_B85","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet."},{"key":"2022020316231843900_B86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-139468","article-title":"VLS-101, a ROR1-targeting antibody-drug conjugate, demonstrates a predictable safety profile and clinical efficacy in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma [oral abstract]","volume":"136","author":"Wang","year":"2020","journal-title":"Blood."},{"issue":"18","key":"2022020316231843900_B87","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol."},{"key":"2022020316231843900_B88","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136659","article-title":"Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy [oral abstract]","volume":"136","author":"Bannerji","year":"2020","journal-title":"Blood."},{"key":"2022020316231843900_B89","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-118344","article-title":"Mosunetuzumab, a full-length bispecific CD20\/CD3 antibody, displays clinical activity in relapsed\/refractory B-cell non-Hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study [abstract]","volume":"132","author":"Budde","year":"2018","journal-title":"Blood."},{"key":"2022020316231843900_B90","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines [abstract]","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood."},{"key":"2022020316231843900_B91","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.7518","article-title":"Subcutaneous epcoritamab in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma: safety profile and antitumor activity [abstract]","volume":"39","author":"Clausen","year":"2021","journal-title":"J Clin Oncol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/5\/666\/1866442\/bloodbld2021013326c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/5\/666\/1866442\/bloodbld2021013326c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T16:02:39Z","timestamp":1699718559000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/5\/666\/477438\/Therapeutic-options-for-relapsed-refractory-mantle"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,2,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021013326","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]}}}